Abiopharma

🔍 Ryder Steven (Executive)

Company: MBX Biosciences, Inc. (MBX)

Report Date: 2026-06-04

Detailed Transactions and Holdings:

• Acquired 12,500 shares of Stock option (right to buy) at $30.91 per share (Derivative)
  Date: 2026-06-04 | Code: A | Expires: 2036-06-04 | equity_swap_involved: false | shares_owned_after: 12,500.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.